These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32341336)

  • 1. DuoHexaBody-CD37
    Oostindie SC; van der Horst HJ; Kil LP; Strumane K; Overdijk MB; van den Brink EN; van den Brakel JHN; Rademaker HJ; van Kessel B; van den Noort J; Chamuleau MED; Mutis T; Lindorfer MA; Taylor RP; Schuurman J; Parren PWHI; Beurskens FJ; Breij ECW
    Blood Cancer J; 2020 Apr; 10(3):30. PubMed ID: 32341336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
    Oostindie SC; van der Horst HJ; Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; VanDerMeid KR; Strumane K; Chamuleau MED; Mutis T; de Jong RN; Schuurman J; Breij ECW; Beurskens FJ; Parren PWHI; Taylor RP
    Haematologica; 2019 Sep; 104(9):1841-1852. PubMed ID: 30792198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.
    Rafiq S; Siadak A; Butchar JP; Cheney C; Lozanski G; Jacob NK; Lapalombella R; McGourty J; Moledor M; Lowe R; Setter B; Jones J; Flynn JM; Andritsos L; Devine S; Mo X; Jarjoura D; Tridandapani S; Algate P; Byrd JC; Muthusamy N
    MAbs; 2013; 5(5):723-35. PubMed ID: 23883821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
    Deckert J; Park PU; Chicklas S; Yi Y; Li M; Lai KC; Mayo MF; Carrigan CN; Erickson HK; Pinkas J; Lutz RJ; Chittenden T; Lambert JM
    Blood; 2013 Nov; 122(20):3500-10. PubMed ID: 24002446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.
    Heider KH; Kiefer K; Zenz T; Volden M; Stilgenbauer S; Ostermann E; Baum A; Lamche H; Küpcü Z; Jacobi A; Müller S; Hirt U; Adolf GR; Borges E
    Blood; 2011 Oct; 118(15):4159-68. PubMed ID: 21795744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
    Pereira DS; Guevara CI; Jin L; Mbong N; Verlinsky A; Hsu SJ; Aviña H; Karki S; Abad JD; Yang P; Moon SJ; Malik F; Choi MY; An Z; Morrison K; Challita-Eid PM; Doñate F; Joseph IB; Kipps TJ; Dick JE; Stover DR
    Mol Cancer Ther; 2015 Jul; 14(7):1650-60. PubMed ID: 25934707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies.
    Smolewski P; Robak P; Cebula-Obrzut B; Misiewicz M; Mędra A; Majchrzak A; Witkowska M; Stromatt S; Robak T
    Eur J Cancer; 2014 Oct; 50(15):2677-84. PubMed ID: 25154027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies.
    Bobrowicz M; Kubacz M; Slusarczyk A; Winiarska M
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.
    Yu B; Mao Y; Yuan Y; Yue C; Wang X; Mo X; Jarjoura D; Paulaitis ME; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
    Biomaterials; 2013 Aug; 34(26):6185-93. PubMed ID: 23726226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells.
    Krause G; Patz M; Isaeva P; Wigger M; Baki I; Vondey V; Kerwien S; Kuckertz M; Brinker R; Claasen J; Frenzel LP; Wendtner CM; Heider KH; Hallek M
    Leukemia; 2012 Mar; 26(3):546-9. PubMed ID: 21886169
    [No Abstract]   [Full Text] [Related]  

  • 11. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.
    Beckwith KA; Frissora FW; Stefanovski MR; Towns WH; Cheney C; Mo X; Deckert J; Croce CM; Flynn JM; Andritsos LA; Jones JA; Maddocks KJ; Lozanski G; Byrd JC; Muthusamy N
    Leukemia; 2014 Jul; 28(7):1501-10. PubMed ID: 24445867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies.
    Qi J; Chen SS; Chiorazzi N; Rader C
    Methods; 2019 Feb; 154():70-76. PubMed ID: 30145356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
    Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2553. PubMed ID: 30524421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and characterization of a bispecific anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.
    Li B; Zhang X; Shi S; Zhao L; Zhang D; Qian W; Zheng L; Gao J; Wang H; Guo Y
    Cancer Res; 2010 Aug; 70(15):6293-302. PubMed ID: 20631068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.
    Zhao X; Lapalombella R; Joshi T; Cheney C; Gowda A; Hayden-Ledbetter MS; Baum PR; Lin TS; Jarjoura D; Lehman A; Kussewitt D; Lee RJ; Caligiuri MA; Tridandapani S; Muthusamy N; Byrd JC
    Blood; 2007 Oct; 110(7):2569-77. PubMed ID: 17440052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.
    Scarfò I; Ormhøj M; Frigault MJ; Castano AP; Lorrey S; Bouffard AA; van Scoyk A; Rodig SJ; Shay AJ; Aster JC; Preffer FI; Weinstock DM; Maus MV
    Blood; 2018 Oct; 132(14):1495-1506. PubMed ID: 30089630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
    Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
    J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
    Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
    Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies.
    Witkowska M; Smolewski P; Robak T
    Expert Opin Investig Drugs; 2018 Feb; 27(2):171-177. PubMed ID: 29323537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
    Ward E; Mittereder N; Kuta E; Sims GP; Bowen MA; Dall'Acqua W; Tedder T; Kiener P; Coyle AJ; Wu H; Jallal B; Herbst R
    Br J Haematol; 2011 Nov; 155(4):426-37. PubMed ID: 21902688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.